Stockreport

Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for ...

Rafael Holdings, Inc. Class B  (RFL) 
NASDAQ:AMEX Investor Relations: morningstar.com/funds/xnas/rytnx/quote.html
PDF CRANBURY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based t [Read more]